Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab with weekly carboplatin and paclitaxel as second-line therapy for advanced malignant melanoma
2008-006191-30Phase 2Active
- Sponsor
- Fondazione Luigi Maria Monti IDI-IRCCS
- Start
- Dec 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, carboplatin and paclitaxel in melanoma, sponsored by Fondazione Luigi Maria Monti IDI-IRCCS. Primary endpoint: Partial and complete response rate. Started Dec 2008; status: active.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-006191-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006191-30.